Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory
Breaking News
- Brexit – Implications For the Pharma Industry in Ireland The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,...
- EMA to Work With Stakeholders to Improve Product Information For EU Medicines The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in...
- Diaceutics Wins at Export Industry Awards Diaceutics, the Irish data insights and solutions company helping patients receive potentially lifesaving medicine through better testing, won the Small & Emerging Exporter of the Year Award at the recent Export...
- Brexit – Key Issues For the Pharmaceutical Industry Brexit – the stark reality is that the UK’s EU membership and the application of all EU legislation in the UK ends automatically at midnight on 30th March 2019! Current understanding...
- European Commission Diagnoses the State of Health in the EU Only by rethinking our health systems can we ensure that they remain fit-for-purpose and provide patient-centred care. This is what the 28 Country Health Profiles recently published by the Commission,...
Dublin-domiciled Medtronic, the world’s largest standalone medical device maker, saw profits more than double at its main Irish subsidiary last
Roche’s oral ALK inhibitor, Alecensa, has been conditionally approved in the European Union as a monotherapy for anaplastic lymphoma kinase-positive
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East
Alnwick-based research and development company, Arc Trinova Ltd, trading as Arcinova, recently received approval for funding from the UK’s Rural
Lanthio Pharma has initiated a Phase I clinical trial with its lanthipeptide candidate MOR107, which is being developed as a
Scientists at Emory University’s Winship Cancer Institute are on a mission to unlock the mysteries of lung cancer cells that
Researchers at Eindhoven University of Technology (TU/e) present a new method that should enable controlled drug delivery into the bloodstream
Cambridge Research Biochemicals (CRB), specialist in the synthesis of custom peptides and antibody production has announced the release of its new
Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the
Strong product pipeline will drive double-digit growth rates in the Western Europe and US markets, finds Frost & Sullivan’s Transformational
Faron Pharmaceuticals has recruited its first patient to a phase II clinical trial of its lead drug, Traumakine, in the
UK-based rare and speciality diseases group Mereo BioPharma says its brittle bone disease drug BPS-804 has been accepted to participate
Developer of consumer healthcare products, Leman Micro Devices (LMD) has announced that its Health Sensor & App will be submitted
On Feb. 2, 2017, FDA issued a warning letter to Sato Pharmaceutical Co., Ltd. after inspectors found current good manufacturing
Sartorius announced on Feb. 17, 2017 that it was partnering with the European Molecular Biology Laboratory (EMBL) research institute to advance
Modus Therapeutics has raised €3.4M to support the completion of a Phase II trial for sickle cell disease, a painful condition
People living in Ayrshire and Arran who have some of the most common forms of avoidable sight loss will now
Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by
Advertisements
